- Home
- EDTK vs PSTV Comparison
EDTK vs PSTV Comparison
Compare EDTK & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- PSTV
- Stock Information
- Founded
- EDTK 2013
- PSTV 1996
- Country
- EDTK China
- PSTV United States
- Employees
- EDTK N/A
- PSTV N/A
- Industry
- EDTK Other Consumer Services
- PSTV Medical/Dental Instruments
- Sector
- EDTK Real Estate
- PSTV Health Care
- Exchange
- EDTK Nasdaq
- PSTV Nasdaq
- Market Cap
- EDTK 16.4M
- PSTV 17.0M
- IPO Year
- EDTK 2020
- PSTV N/A
- Fundamental
- Price
- EDTK $1.00
- PSTV $0.45
- Analyst Decision
- EDTK
- PSTV Strong Buy
- Analyst Count
- EDTK 0
- PSTV 4
- Target Price
- EDTK N/A
- PSTV $7.88
- AVG Volume (30 Days)
- EDTK 9.8K
- PSTV 8.4M
- Earning Date
- EDTK 08-08-2025
- PSTV 08-14-2025
- Dividend Yield
- EDTK N/A
- PSTV N/A
- EPS Growth
- EDTK N/A
- PSTV N/A
- EPS
- EDTK N/A
- PSTV N/A
- Revenue
- EDTK $893,690.00
- PSTV $5,317,000.00
- Revenue This Year
- EDTK N/A
- PSTV $2.95
- Revenue Next Year
- EDTK N/A
- PSTV $7.89
- P/E Ratio
- EDTK N/A
- PSTV N/A
- Revenue Growth
- EDTK N/A
- PSTV N/A
- 52 Week Low
- EDTK $0.80
- PSTV $0.16
- 52 Week High
- EDTK $1.20
- PSTV $2.31
- Technical
- Relative Strength Index (RSI)
- EDTK 46.57
- PSTV 43.79
- Support Level
- EDTK $1.00
- PSTV $0.39
- Resistance Level
- EDTK $1.16
- PSTV $0.54
- Average True Range (ATR)
- EDTK 0.05
- PSTV 0.05
- MACD
- EDTK -0.01
- PSTV -0.02
- Stochastic Oscillator
- EDTK 2.86
- PSTV 22.96
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).